Ezh-108- A Phase I, Open-Label Multi-Dose Two-Part Study To Characterize The Effects Of A Strong Cyp3a4 Inhibitor And A Strong Cyp3a4 Inducer On The Steady-State Pharmacokinetics Of Tazemetostat (Epz-6438) In Subjects With Advanced Malignancies
Posted Date: May 6, 2021
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to characterize the steady-state PK of oral Tazemetostat and its metabolite EPZ 6930 when administered as a single and twice daily dose in subjects with advanced malignancies while taken alone or in combination with either itraconazole or rifampin.
Histologically And/Or Cytologically Confirmed Advanced Metastatic Or Unresectable Solid Tumors Has Progressed After Treatment For Which There Are No Standard Therapies Available, Ecog 0-2, Adequate Organ Function As Defined By Protocol, Life Expectancy Of > 3 Months, No Known Hypersensitivity To Any Of The Components Of Tazemetostat, No Uncontrolled Concurrent Illness, Or Ongoing Or Active Infection That Would Limit Compliance With Study Requirements, No History Of Drug Abuse (Including Alcohol) Within The Last 6 Months, No Marijuana Use.
Phase 1, Advanced Malignancies
For More Information:
Uc Cancer Center